AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,735.00
Bid: 7,728.00
Ask: 7,730.00
Change: 55.00 (0.72%)
Spread: 2.00 (0.03%)
Open: 7,682.00
High: 7,745.00
Low: 7,673.00
Yest. Close: 7,680.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca advances Covid-19 antibodies with US funding

Mon, 12th Oct 2020 07:29

(Sharecast News) - AstraZeneca announced on Monday that its long-acting antibody (LAAB) combination for Covid-19, AZD7442, would advance into two phase 3 clinical trials in more than 6,000 participants both in and outside the US in the coming weeks.
The FTSE 100 pharmaceuticals giant said the LAABs had been engineered with its proprietary half-life extension technology to increase the durability of the therapy for six to 12 months following a single administration.

It said the combination of two LAABs were also designed to reduce the risk of resistance developed by the SARS-CoV-2 virus.

The company said it had received support of around $486m (£372.51m) from the US government for the development and supply of AZD7442, under an agreement with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the US Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

One trial would evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12 months, in around 5,000 participants.

The second trial would evaluate post-exposure prophylaxis and pre-emptive treatment in about 1,100 participants.

AstraZeneca said it was planning additional trials to evaluate AZD7442 in approximately 4,000 patients for the treatment of Covid-19.

It said it planned to supply up to 100,000 doses towards the end of 2020, with the US government able to acquire up to an additional one million doses in 2021 under a separate agreement.

"This agreement with the US government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating Covid-19 infections," said chief executive officer Pascal Soriot.

"We will be evaluating the LAAB combination in different settings from prophylaxis, to outpatient treatment to hospitalisation, with a focus on helping the most vulnerable people."

The firm said LAABs mimicked natural antibodies, and had the potential to treat and prevent disease progression in patients already infected with the virus, as well as to be given as a preventative intervention prior to exposure to the virus.

A LAAB combination could be complementary to vaccines as a prophylactic agent, for example for people for whom a vaccine might not be appropriate, or to provide added protection for high-risk populations.

It could also be used to treat people who had been infected.

AstraZeneca said the agreement built on previous funding of more than $25m from US government agencies for the discovery and evaluation of the monoclonal antibodies, as well as the phase 1 clinical trial started in August to assess safety, tolerability and pharmacokinetics of AZD7442 in healthy individuals.

More News

UPDATE 1-EU has not yet ordered more AstraZeneca vaccines, says internal market commissioner

(Adds extra cost for Pfizer vaccine, background)PARIS, May 9 (Reuters) - hThe European Union has not yet made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said o...

Today 13:27

UPDATE 2-EU has not ordered AstraZeneca vaccines beyond June - Commissioner

(Adds Macron comments)PARIS, May 9 (Reuters) - The European Union has not made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday, after the EU signed a...

Today 13:27

REFILE-UPDATE 2-EU has not ordered AstraZeneca vaccines beyond June - Commissioner

(Amends media denominator)PARIS, May 9 (Reuters) - The European Union has not made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday, after the EU sign...

Today 13:27

EU's Breton: EU did not renew Astrazeneca COVID-19 vaccine order for after June

PARIS, May 9 (Reuters) - European Internal Market Commissioner Thierry Breton said on Sunday the European Commission did not renew its order for AstraZeneca vaccines against COVID-19 for after June.The European Commission last month launched legal...

Today 11:30

Sri Lanka approves Pfizer COVID vaccine for emergency use

By Waruna KarunatilakeCOLOMBO, May 8 (Reuters) - Sri Lanka on Saturday approved Pfizer's COVID-19 vaccine for emergency use in Sri Lanka, as the island nation battles a third wave of the virus, while suffering a restricted supply of vaccines from ...

8 May 21 09:33

Britain free of coronavirus by August, outgoing vaccine task force chief says -Telegraph

May 7 (Reuters) - The new coronavirus will no longer be circulating in Britain by August, the government's departing vaccine taskforce chief Clive Dix told the Daily Telegraph on Friday."Sometime in August, we will have no circulating virus in th...

8 May 21 00:15

UPDATE 1-AstraZeneca weighs seeking full U.S. approval for COVID shot - WSJ

(Adds background related to AstraZeneca vaccine)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive application...

7 May 21 23:23

UPDATE 2-AstraZeneca weighs seeking full, not emergency, U.S. approval for COVID-19 shot - WSJ

(Adds response from AstraZeneca in paragraphs 3 and 4)May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine and instead pursue the more time-intensive appli...

7 May 21 23:23

AstraZeneca weighs seeking full U.S. approval for COVID-19 shot -WSJ

May 7 (Reuters) - AstraZeneca Plc may skip asking the U.S. Food and Drug Administration for emergency-use authorization for its COVID-19 vaccine, and instead pursue the more time-intensive application for a full-fledged license to sell the shot, ...

7 May 21 22:52

INSIGHT-How the U.S. locked up vaccine materials other nations urgently need

By Allison Martell and Euan RochaMay 7 (Reuters) - To fight the pandemic at home, the United States gave its own vaccine manufacturers priority access to American-made materials needed to make the shots.As a result, the U.S. government laid claim n...

7 May 21 16:00

WRAPUP 1-Britain, Germany in role reversal on AstraZeneca vaccine risks

* Britain restricts AstraZeneca to people aged over 40* In Germany, all adults free to get AZ shot on doctor's advice* Germany, with eye on summer hols, shortens gap between doses* EU regulator looking at AZ on reports of neurological illnessBy Al...

7 May 21 15:34

UPDATE 1-Vietnam reports first death in patient who received AstraZeneca COVID-19 vaccine

(Adds details and background)By Khanh VuHANOI, May 7 (Reuters) - Vietnam's health ministry on Friday reported its first death in a patient who received AstraZeneca's COVID-19 vaccine shot, as the country is battling a new outbreak.A 35-year-old fe...

7 May 21 15:31

Vietnam reports first death in patient who received AstraZeneca COVID-19 vaccine

HANOI, May 7 (Reuters) - Vietnam's health ministry on Friday reported its first death in a patient who received AstraZeneca's COVID-19 vaccine shot.A 35-year-old female health worker in the southern province of An Giang died on Friday, one day aft...

7 May 21 14:54

UPDATE 1-EU regulator reviews reports of rare nerve disorder after AstraZeneca shot

(Adds details from EMA statement on other vaccines, background)May 7 (Reuters) - Europe's medicines regulator said on Friday it was reviewing reports of a rare nerve-degenerating disorder in people who have received AstraZeneca's COVID-19 vaccine,...

7 May 21 13:15

UPDATE 2-EU reviews reports of rare nerve disorder after AstraZeneca's COVID-19 shot

* EMA reviewing AstraZeneca vaccine for Guillain-Barre syndrome* Rare nerve syndrome also linked some vaccinations in past* EMA also assessing heart inflammation with Pfizer, Moderna shots* Studies into possible links to rare blood clots ongoing (...

7 May 21 13:15

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.